The challenge of managing fusariosis

References

• Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: Focus on voriconazole. Ther Clin Risk Manag 2007; 3:1165 - 1173
   PubMedGoogle Scholar
• Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999 - 1008
   PubMed Web of Science ®Google Scholar
• Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 2006; 91:1068 - 1075
   PubMed Web of Science ®Google Scholar
• Wingard JR. The changing face of invasive fungal infections in hematopoietic cell transplant recipients. Curr Opin Oncol 2005; 17:89 - 92
   PubMed Web of Science ®Google Scholar
• Maertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007; 78:275 - 282
   PubMed Web of Science ®Google Scholar
• Chandrasekar P. Invasive mold infections: recent advances in management approaches. Leuk Lymphoma 2009; 50:703 - 715
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695 - 704
   PubMed Web of Science ®Google Scholar
• Dignani MC, Anaissie E. Human fusariosis. Clin Microbiol Infect 2004; 10:Suppl 1 67 - 75
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al. Fusarium infection in hematopoietic stem cell transplant recipients. Clin Infect Dis 2004; 38:1237 - 1242
   PubMed Web of Science ®Google Scholar
• Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol 2006; 55:809 - 818
   PubMed Web of Science ®Google Scholar
• Nucci M, Marr KA. Emerging fungal diseases. Clin Infect Dis 2005; 41:521 - 526
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Emerging fungi. Infect Dis Clin North Am 2006; 20:563 - 579
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Solza C, et al. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer 2003; 98:315 - 319
   PubMed Web of Science ®Google Scholar
• Cornely OA. Aspergillus to Zygomycetes: causes, risk factors, prevention, and treatment of invasive fungal infections. Infection 2008; 36:296 - 313
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Kontoyiannis DP. Fusarium infections in critically ill patients. Semin Respir Crit Care Med 2004; 25:159 - 169
   PubMed Web of Science ®Google Scholar
• Chen SC, Playford EG, Sorrell TC. Antifungal therapy in invasive fungal infections. Curr Opin Pharmacol 2010; 10:522 - 530
   PubMed Web of Science ®Google Scholar
• Azor M, Cano J, Gene J, Guarro J. High genetic diversity and poor in vitro response to antifungals of clinical strains of Fusarium oxysporum. J Antimicrob Chemother 2009; 63:1152 - 1155
   PubMed Web of Science ®Google Scholar
• Tortorano AM, Prigitano A, Dho G, Esposto MC, Gianni C, Grancini A, et al. Species distribution and in vitro antifungal susceptibility patterns of 75 clinical isolates of Fusarium spp. from northern Italy. Antimicrob Agents Chemother 2008; 52:2683 - 2685
   PubMed Web of Science ®Google Scholar
• Guinea J, Pelaez T, Recio S, Torres-Narbona M, Bouza E. In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, Candida, Aspergillus, Fusarium, and Scedosporium species. Antimicrob Agents Chemother 2008; 52:1396 - 1400
   PubMed Web of Science ®Google Scholar
• Espinel-Ingroff A, Johnson E, Hockey H, Troke P. Activities of voriconazole, itraconazole and amphotericin B in vitro against 590 moulds from 323 patients in the voriconazole Phase III clinical studies. J Antimicrob Chemother 2008; 61:616 - 620
   PubMed Web of Science ®Google Scholar
• Alastruey-Izquierdo A, Cuenca-Estrella M, Monzon A, Mellado E, Rodriguez-Tudela JL. Antifungal susceptibility profile of clinical Fusarium spp. isolates identified by molecular methods. J Antimicrob Chemother 2008; 61:805 - 809
   PubMed Web of Science ®Google Scholar
• Cordoba S, Rodero L, Vivot W, Abrantes R, Davel G, Vitale RG. In vitro interactions of antifungal agents against clinical isolates of Fusarium spp. Int J Antimicrob Agents 2008; 31:171 - 174
   PubMed Web of Science ®Google Scholar
• Ruiz-Cendoya M, Marine M, Guarro J. Combined therapy in treatment of murine infection by Fusarium solani. J Antimicrob Chemother 2008; 62:543 - 546
   PubMed Web of Science ®Google Scholar
• Ortoneda M, Capilla J, Pastor FJ, Pujol I, Guarro J. Efficacy of liposomal amphotericin B in treatment of systemic murine fusariosis. Antimicrob Agents Chemother 2002; 46:2273 - 2275
   PubMed Web of Science ®Google Scholar
• Pfaller MA, Messer SA, Georgopapadakou N, Martell LA, Besterman JM, Diekema DJ. Activity of MGCD290, a Hos2 histone deacetylase inhibitor, in combination with azole antifungals against opportunistic fungal pathogens. J Clin Microbiol 2009; 47:3797 - 3804
   PubMed Web of Science ®Google Scholar
• Smith WL, Edlind TD. Histone deacetylase inhibitors enhance Candida albicans sensitivity to azoles and related antifungals: correlation with reduction in CDR and ERG upregulation. Antimicrob Agents Chemother 2002; 46:3532 - 3539
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Nguyen MH. The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis. J Antimicrob Chemother 1998; 41:127 - 130
   PubMed Web of Science ®Google Scholar
• Stanzani M, Vianelli N, Bandini G, Paolini S, Arpinati M, Bonifazi F, et al. Successful treatment of disseminated Fusariosis after allogeneic hematopoietic stem cell transplantation with the combination of voriconazole and liposomal amphotericin B. J Infect 2006; 53:e243 - e246
   PubMed Web of Science ®Google Scholar
• Patterson TF, Mackool BT, Gilman MD, Piris A. Case records of the Massachusetts General Hospital. Case 22-2009. A 59-year-old man with skin and pulmonary lesions after chemotherapy for leukemia [corrected]. N Engl J Med 2009; 361:287 - 296
   PubMed Web of Science ®Google Scholar
• Cesaro S, Marinello S, Alessia B, Alaggio R, Rossi L, Toffolutti T, et al. Successful treatment of disseminated fusariosis in a child with acute myelogenous leukaemia with medical and surgical approach. Mycoses 2010; 53:181 - 185
   PubMed Web of Science ®Google Scholar
• Busemann C, Kruger W, Schwesinger G, Kallinich B, Schroder G, Abel P, et al. Myocardial and aortal involvement in a case of disseminated infection with Fusarium solani after allogeneic stem cell transplantation: report of a case. Mycoses 2009; 52:372 - 376
   PubMed Web of Science ®Google Scholar
• Vagace JM, Sanz-Rodriguez C, Casado MS, Alonso N, Garcia-Dominguez M, de la Llana FG, et al. Resolution of disseminated fusariosis in a child with acute leukemia treated with combined antifungal therapy: a case report. BMC Infect Dis 2007; 7:40
   PubMed Web of Science ®Google Scholar
• Selleslag D. A case of fusariosis in an immunocompromised patient successfully treated with liposomal amphotericin B. Acta Biomed 2006; 77:32 - 35
   PubMedGoogle Scholar
• Carneiro HA, Coleman JJ, Restrepo A, Mylonakis E. Fusarium infection in lung transplant patients: report of 6 cases and review of the literature. Medicine (Baltimore) 2011; 90:69 - 80
   PubMed Web of Science ®Google Scholar
• Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B, et al. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol 2003; 41:4898 - 4900
   PubMed Web of Science ®Google Scholar
• Guzman-Cottrill JA, Zheng X, Chadwick EG. Fusarium solani endocarditis successfully treated with liposomal amphotericin B and voriconazole. Pediatr Infect Dis J 2004; 23:1059 - 1061
   PubMed Web of Science ®Google Scholar
• Cooke NS, Feighery C, Armstrong DK, Walsh M, Dempsey S. Cutaneous Fusarium solani infection in childhood acute lymphoblastic leukaemia. Clin Exp Dermatol 2009; 34:e117 - e119
   PubMed Web of Science ®Google Scholar
• Ho DY, Lee JD, Rosso F, Montoya JG. Treating disseminated fusariosis: amphotericin B, voriconazole or both?. Mycoses 2007; 50:227 - 231
   PubMed Web of Science ®Google Scholar
• Lodato F, Tame MR, Montagnani M, Sambri V, Liguori G, Azzaroli F, et al. Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: an emerging fungal agent. Liver Transpl 2006; 12:1711 - 1714
   PubMed Web of Science ®Google Scholar
• Cudillo L, Tendas A, Picardi A, Dentamaro T, Del Principe MI, Amadori S, et al. Successful treatment of disseminated fusariosis with high dose liposomal amphotericin-B in a patient with acute lymphoblastic leukemia. Ann Hematol 2006; 85:136 - 138
   PubMed Web of Science ®Google Scholar
• Letscher-Bru V, Campos F, Waller J, Randriamahazaka R, Candolfi E, Herbrecht R. Successful outcome of treatment of a disseminated infection due to Fusarium dimerum in a leukemia patient. J Clin Microbiol 2002; 40:1100 - 1102
   PubMed Web of Science ®Google Scholar
• Campo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998–2009. J Infect 2010; 60:331 - 337
   PubMed Web of Science ®Google Scholar
• Perfect JR. Treatment of non-Aspergillus moulds in immunocompromised patients, with amphotericin B lipid complex. Clin Infect Dis 2005; 40:S401 - S408
   PubMed Web of Science ®Google Scholar
• Scott LJ, Simpson D. Voriconazole : a review of its use in the management of invasive fungal infections. Drugs 2007; 67:269 - 298
   PubMed Web of Science ®Google Scholar
• Peman J, Salavert M, Canton E, Jarque I, Roma E, Zaragoza R, et al. Voriconazole in the management of nosocomial invasive fungal infections. Ther Clin Risk Manag 2006; 2:129 - 158
   PubMedGoogle Scholar
• Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122 - 1131
   PubMed Web of Science ®Google Scholar
• Lortholary O, Obenga G, Biswas P, Caillot D, Chachaty E, Bienvenu AL, et al. International retrospective analysis of 73 cases of invasive fusariosis treated with voriconazole. Antimicrob Agents Chemother 2010; 54:4446 - 4450
   PubMed Web of Science ®Google Scholar
• Cudillo L, Girmenia C, Santilli S, Picardi A, Dentamaro T, Tendas A, et al. Breakthrough fusariosis in a patient with acute lymphoblastic leukemia receiving voriconazole prophylaxis. Clin Infect Dis 2005; 40:1212 - 1213
   PubMed Web of Science ®Google Scholar
• Kwon DS, Mylonakis E. Posaconazole: a new broad-spectrum antifungal agent. Expert Opin Pharmacother 2007; 8:1167 - 1178
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005; 3:467 - 487
   PubMedGoogle Scholar
• Groll AH, Walsh TJ. Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections. Mycoses 2006; 49:7 - 16
   PubMed Web of Science ®Google Scholar
• Raad II, Hachem RY, Herbrecht R, Graybill JR, Hare R, Corcoran G, et al. Posaconazole as salvage treatment for invasive fusariosis in patients with underlying hematologic malignancy and other conditions. Clin Infect Dis 2006; 42:1398 - 1403
   PubMed Web of Science ®Google Scholar
• Wilson DT, Drew RH, Perfect JR. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 2009; 168:313 - 327
   PubMed Web of Science ®Google Scholar
• Langner S, Staber PB, Neumeister P. Posaconazole in the management of refractory invasive fungal infections. Ther Clin Risk Manag 2008; 4:747 - 758
   PubMedGoogle Scholar
• Johnson MD, Perfect JR. Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep 2010; 4:87 - 95
   PubMedGoogle Scholar
• Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs 2006; 15:579 - 602
   PubMed Web of Science ®Google Scholar
• Lupinetti FM, Giller RH, Trigg ME. Operative treatment of Fusarium fungal infection of the lung. Ann Thorac Surg 1990; 49:991 - 992
   PubMed Web of Science ®Google Scholar
• Velasco E, Martins CA, Nucci M. Successful treatment of catheter-related fusarial infection in immunocompromised children. Eur J Clin Microbiol Infect Dis 1995; 14:697 - 699
   PubMed Web of Science ®Google Scholar
• Spielberger RT, Falleroni MJ, Coene AJ, Larson RA. Concomitant amphotericin B therapy, granulocyte transfusions, and GM-CSF administration for disseminated infection with Fusarium in a granulocytopenic patient. Clin Infect Dis 1993; 16:528 - 530
   PubMed Web of Science ®Google Scholar
• Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909 - 920
   PubMed Web of Science ®Google Scholar
• Anaissie EJ, Kuchar RT, Rex JH, Francesconi A, Kasai M, Muller FM, et al. Fusariosis associated with pathogenic Fusarium species colonization of a hospital water system: a new paradigm for the epidemiology of opportunistic mold infections. Clin Infect Dis 2001; 33:1871 - 1878
   PubMed Web of Science ®Google Scholar
• Thompson GR 3rd, Wiederhold NP. Isavuconazole: A Comprehensive review of spectrum of activity of a new triazole. Mycopathologia 2010; 170:291 - 293
   PubMed Web of Science ®Google Scholar
• Spiess B, Seifarth W, Hummel M, Frank O, Fabarius A, Zheng C, et al. DNA microarray-based detection and identification of fungal pathogens in clinical samples from neutropenic patients. J Clin Microbiol 2007; 45:3743 - 3753
   PubMed Web of Science ®Google Scholar
• Lau A, Chen S, Sorrell T, Carter D, Malik R, Martin P, et al. Development and clinical application of a panfungal PCR assay to detect and identify fungal DNA in tissue specimens. J Clin Microbiol 2007; 45:380 - 385
   PubMed Web of Science ®Google Scholar
• Ahmad S, Khan ZU, Theyyathel AM. Development of a nested PCR assay for the detection of Fusarium solani DNA and its evaluation in the diagnosis of invasive fusariosis using an experimental mouse model. Mycoses 2010; 53:40 - 47
   PubMed Web of Science ®Google Scholar
• Khan ZU, Ahmad S, Theyyathel AM. Diagnostic value of DNA and (1-->3)-beta-D-glucan detection in serum and bronchoalveolar lavage of mice experimentally infected with Fusarium oxysporum. J Med Microbiol 2008; 57:36 - 42
   PubMed Web of Science ®Google Scholar
• Alfonso EC. Genotypic identification of Fusarium species from ocular sources: comparison to morphologic classification and antifungal sensitivity testing (an AOS thesis). Trans Am Ophthalmol Soc 2008; 106:227 - 239
   PubMedGoogle Scholar
• Debourgogne A, Gueidan C, Hennequin C, Contet-Audonneau N, de Hoog S, Machouart M. Development of a new MLST scheme for differentiation of Fusarium solani Species Complex (FSSC) isolates. J Microbiol Methods 2010; 82:319 - 323
   PubMed Web of Science ®Google Scholar
• Marinach-Patrice C, Lethuillier A, Marly A, Brossas JY, Gene J, Symoens F, et al. Use of mass spectrometry to identify clinical Fusarium isolates. Clin Microbiol Infect 2009; 15:634 - 642
   PubMed Web of Science ®Google Scholar
• Landlinger C, Preuner S, Willinger B, Haberpursch B, Racil Z, Mayer J, et al. Species-specific identification of a wide range of clinically relevant fungal pathogens by use of Luminex xMAP technology. J Clin Microbiol 2009; 47:1063 - 1073
   PubMed Web of Science ®Google Scholar
• Landlinger C, Baskova L, Preuner S, Willinger B, Buchta V, Lion T. Identification of fungal species by fragment length analysis of the internally transcribed spacer 2 region. Eur J Clin Microbiol Infect Dis 2009; 28:613 - 622
   PubMed Web of Science ®Google Scholar
• Balajee SA, Borman AM, Brandt ME, Cano J, Cuenca-Estrella M, Dannaoui E, et al. Sequence-based identification of Aspergillus, Fusarium, and Mucorales species in the clinical mycology laboratory: where are we and where should we go from here?. J Clin Microbiol 2009; 47:877 - 884
   PubMed Web of Science ®Google Scholar
• Azor M, Gene J, Cano J, Manikandan P, Venkatapathy N, Guarro J. Less-frequent Fusarium species of clinical interest: correlation between morphological and molecular identification and antifungal susceptibility. J Clin Microbiol 2009; 47:1463 - 1468
   PubMed Web of Science ®Google Scholar
• Branski LK, Al-Mousawi A, Rivero H, Jeschke MG, Sanford AP, Herndon DN. Emerging infections in burns. Surg Infect (Larchmt) 2009; 10:389 - 397
   PubMed Web of Science ®Google Scholar
• Wheeler MS, McGinnis MR, Schell WA, Walker DH. Fusarium infection in burned patients. Am J Clin Pathol 1981; 75:304 - 311
   PubMed Web of Science ®Google Scholar
• Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Monzon A, Buitrago MJ, Rodriguez-Tudela JL. Activity profile in vyitro of micafungin against Spanish clinical isolates of common and emerging species of yeasts and molds. Antimicrob Agents Chemother 2009; 53:2192 - 2195
   PubMed Web of Science ®Google Scholar
• Lass-Florl C, Mayr A, Perkhofer S, Hinterberger G, Hausdorfer J, Speth C, et al. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing. Antimicrob Agents Chemother 2008; 52:3637 - 3641
   PubMed Web of Science ®Google Scholar